Gestational Diabetes Screening

Gestational diabetes mellitus (GDM) screening originated with O'Sullivan and Mahan's 1964 criteria, which were designed to predict future maternal type 2 diabetes rather than to prevent perinatal complications. The traditional two-step approach — a 50g glucose challenge test (GCT) followed by a diagnostic 100g oral glucose tolerance test (OGTT) in screen-positive women — became standard practice in North America. However, the diagnostic thresholds were arbitrary, derived from statistical analyses rather than perinatal outcome data. International variation in screening approaches and diagnostic criteria was enormous, creating confusion about the true prevalence and optimal management of GDM. The fundamental question remained unanswered: at what glucose level does the risk of adverse perinatal outcomes increase?

The Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study, published in the New England Journal of Medicine in 2008, was the landmark international observational study that transformed the field. HAPO studied 23,316 pregnant women across 15 centers in 9 countries using a 75g OGTT at 24-32 weeks, with results blinded to clinicians. The study demonstrated a continuous linear relationship between maternal glucose levels and adverse outcomes (birth weight >90th percentile, cord C-peptide >90th percentile, primary cesarean delivery, neonatal hypoglycemia) — with no clear threshold below which risk was absent. This continuous risk finding fundamentally challenged the concept of a binary diagnosis and led to new outcome-based diagnostic criteria from IADPSG.

The IADPSG (International Association of Diabetes and Pregnancy Study Groups) used HAPO data to establish new diagnostic criteria based on the glucose levels at which odds of adverse outcomes reached 1.75 times the mean — creating a one-step 75g OGTT diagnostic approach. Meanwhile, the ACHOIS trial (2005) and the Landon trial (2009) provided the critical RCT evidence that treating mild GDM reduces adverse outcomes. ACHOIS randomized 1,000 women with GDM to treatment versus routine care and showed significant reductions in serious perinatal complications (1% vs 4%) and preeclampsia. Landon's trial randomized 958 women with mild GDM and demonstrated reduced macrosomia, shoulder dystocia, preeclampsia, and cesarean delivery with treatment. These trials confirmed that identifying and treating GDM matters, fueling the debate over optimal screening strategy.

Guidelines remain divided. The WHO, FIGO, and the Endocrine Society adopted the IADPSG one-step 75g OGTT criteria (fasting ≥5.1, 1h ≥10.0, 2h ≥8.5 mmol/L). However, ACOG and the NIH Consensus Development Panel continue to recommend the traditional two-step approach (50g GCT screening followed by 100g OGTT diagnostic test) based on concerns that the one-step approach would dramatically increase GDM prevalence (from ~6% to ~18%) without proven benefit in terms of outcomes when applied as a screening strategy. The ongoing debate reflects genuine uncertainty about whether diagnosing and treating milder degrees of hyperglycemia identified by the one-step approach improves outcomes enough to justify the increased healthcare burden.

The one-step vs two-step debate continues as one of the most contentious issues in obstetric practice. The SCREENING FOR GESTATIONAL DIABETES (SCREENR) and other pragmatic trials are underway to directly compare the two approaches on maternal and neonatal outcomes. Rising obesity rates worldwide are increasing GDM prevalence regardless of screening strategy. There is growing interest in early pregnancy screening (before 20 weeks) to identify women with previously undiagnosed pre-existing diabetes and early-onset GDM, though optimal early screening approaches remain undefined. Continuous glucose monitoring (CGM) during pregnancy is being studied as an alternative diagnostic and management tool. The long-term metabolic consequences for both mothers (50% lifetime risk of type 2 diabetes) and offspring (increased cardiometabolic risk) drive interest in postpartum follow-up programs and intergenerational prevention strategies.